Janux Therapeutics Inc. (JANX), which made its debut on the Nasdaq last June, remains on-track to submit IND filings for two of its programs this year. The company is developing novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms.
from RTT - Earnings https://ift.tt/6WGJniD
via IFTTT
No comments:
Post a Comment